Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSC for Duchenne Muscular Dystrophy
NCT02235844Phase 1Completed
- Sponsor
- Allergy & Asthma Consultants
- Start
- Sep 2014
- Primary completion
- Sep 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of human umbilical cord mesenchymal stem cells in Duchenne muscular dystrophy (DMD), sponsored by Allergy & Asthma Consultants. Primary endpoint: Adverse Events at 3 months. Started Sep 2014; status: completed.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02235844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02235844.